IFNA1 and systemic lupus erythematosus: Furthermore, within the subpopulation of SLE patients with an IFN signature, therapeutic antibodies that neutralize IFNα (41, 160, 160, 161) or all type I IFNs (by blocking their receptor) (40) have been clinically efficacious in some patients, but not in others.